Larsucosterol - DURECT Corporation
Alternative Names: 25HC3S; DUR-928; DUR-928 sodium - DURECT Corporation; DV-928; Larsucosterol sodium - DURECT CorporationLatest Information Update: 13 Nov 2023
At a glance
- Originator Virginia Commonwealth University
- Developer DURECT Corporation
- Class Anti-inflammatories; Antipsoriatics; Hepatoprotectants; Small molecules; Sterols; Urologics; Vascular disorder therapies
- Mechanism of Action DNA methylation inhibitors; Inflammation mediator modulators; Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alcoholic hepatitis
- Phase I Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Discontinued Acute kidney injury; Atopic dermatitis; Liver disorders; Plaque psoriasis; Primary sclerosing cholangitis; Psoriasis; Stroke
Most Recent Events
- 07 Nov 2023 Efficacy and adverse events data from a phase II trial in Alcoholic hepatitis released by DURECT
- 07 Nov 2023 DURECT plans a phase III registration trial design in the first quarter of 2024
- 30 Sep 2023 National Institute on Alcohol Abuse and Alcoholism completes a phase IIb trial in Alcoholic hepatitis in USA (NCT03917407)